Carmelo Tibaldi

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini et al. · British Journal of Cancer · 2014 · 605 citations · Full text

Medicine, Oncology, Pharmacology +17

Correlation of <i>CDA, ERCC1</i>, and <i>XPD</i> Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients

Carmelo Tibaldi, Elisa Giovannetti, Enrico Vasile et al. · Clinical Cancer Research · 2008 · 208 citations

Medicine, Molecular Genetics, Oncology +17

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Marcello Tiseo, Luca Boni, Francesca Ambrosio et al. · Journal of Clinical Oncology · 2017 · 184 citations

Medicine, Oncology, Pharmacotherapy +12

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

M. Venturini, Andrea Michelotti, Lucia Del Mastro et al. · Journal of Clinical Oncology · 1996 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry

Richard J. Honeywell, K. Yarzadah, Elisa Giovannetti et al. · Journal of Chromatography B · 2010 · 95 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +15